• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

合并症患者的 COVID-19 感染：临床和免疫学见解。

COVID-19 Infection in Patients with Comorbidities: Clinical and Immunological Insight.

机构信息

Department of Medical Microbiology and Immunology, Faculty of Medicine, 68796Assiut University, Assiut, Egypt.

Department of Gastroenterology and Tropical Medicine, Faculty of Medicine, 68796Assiut University, Assiut, Egypt.

出版信息

Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221107889. doi: 10.1177/10760296221107889.

DOI:10.1177/10760296221107889
PMID:35698744
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9201308/
Abstract

AIM

Our study's objectives were to study the clinical and laboratory characteristics that may serve as biomarkers for predicting disease severity, IL-10 levels, and frequencies of different T cell subsets in comorbid COVID-19 patients.

METHODS

Sixty-two hospitalized COVID-19 patients with comorbidities were assessed clinically and radiologically. Blood samples were collected to assess the T lymphocyte subsets by flow cytometry and IL-10 levels by ELISA.

RESULTS

The most common comorbidities observed in COVID-19 patients were diabetes mellitus (DM), hypertension, and malignancies. Common symptoms and signs included fever, cough, dyspnea, fatigue, myalgia, and sore throat. CRP, ferritin, D dimer, LDH, urea, creatinine, and direct bilirubin were significantly increased in patients than controls. Lymphocyte count and CD4 and CD8 T-cells were significantly decreased in comorbid COVID-19 patients, and CD25 and CD45RA expression were increased. CD4 and CD8 regulatory T cells (Tregs) and IL-10 levels were significantly decreased in patients.

CONCLUSIONS

Many parameters were found to be predictive of severity in the comorbid patients in our study. Significant reductions in the levels and activation of CD4 and CD8 T-cells were found. In addition, CD4 and CD8 Tregs were significant decreased in patients, probably pointing to a prominent role of CD8 Tregs in dampening CD4 T-cell activation.

摘要

目的

我们的研究目的是研究可能作为预测疾病严重程度、IL-10 水平和合并 COVID-19 患者不同 T 细胞亚群频率的生物标志物的临床和实验室特征。

方法

对 62 例住院合并 COVID-19 的患者进行临床和影像学评估。采集血样通过流式细胞术评估 T 淋巴细胞亚群，通过 ELISA 评估 IL-10 水平。

结果

COVID-19 患者最常见的合并症是糖尿病（DM）、高血压和恶性肿瘤。常见的症状和体征包括发热、咳嗽、呼吸困难、疲劳、肌痛和咽痛。与对照组相比，CRP、铁蛋白、D 二聚体、LDH、尿素、肌酐和直接胆红素在患者中显著升高。合并 COVID-19 的患者淋巴细胞计数以及 CD4 和 CD8 T 细胞显著减少，CD25 和 CD45RA 表达增加。CD4 和 CD8 调节性 T 细胞（Tregs）和 IL-10 水平显著降低。

结论

在我们的研究中，许多参数被发现可预测合并症患者的严重程度。发现 CD4 和 CD8 T 细胞的水平和激活显著降低。此外，患者的 CD4 和 CD8 Tregs 显著减少，这可能表明 CD8 Tregs 在抑制 CD4 T 细胞活化方面发挥了重要作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a934/9201308/fdfe57bd7b82/10.1177_10760296221107889-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a934/9201308/32f367a3e98d/10.1177_10760296221107889-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a934/9201308/c9789f28f6ce/10.1177_10760296221107889-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a934/9201308/b1f42edc2649/10.1177_10760296221107889-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a934/9201308/f9f9b9044467/10.1177_10760296221107889-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a934/9201308/fdfe57bd7b82/10.1177_10760296221107889-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a934/9201308/32f367a3e98d/10.1177_10760296221107889-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a934/9201308/c9789f28f6ce/10.1177_10760296221107889-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a934/9201308/b1f42edc2649/10.1177_10760296221107889-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a934/9201308/f9f9b9044467/10.1177_10760296221107889-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a934/9201308/fdfe57bd7b82/10.1177_10760296221107889-fig5.jpg

相似文献

1
COVID-19 Infection in Patients with Comorbidities: Clinical and Immunological Insight.合并症患者的 COVID-19 感染：临床和免疫学见解。
Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221107889. doi: 10.1177/10760296221107889.
2
Risk Factors for Mortality of COVID-19 Patient Based on Clinical Course: A Single Center Retrospective Case-Control Study.基于临床病程的 COVID-19 患者死亡风险因素：一项单中心回顾性病例对照研究。
Front Immunol. 2021 Feb 16;12:581469. doi: 10.3389/fimmu.2021.581469. eCollection 2021.
3
Dynamics of cytokines and lymphocyte subsets associated with the poor prognosis of severe COVID-19.与重症 COVID-19 预后不良相关的细胞因子和淋巴细胞亚群的动态变化。
Eur Rev Med Pharmacol Sci. 2020 Dec;24(23):12536-12544. doi: 10.26355/eurrev_202012_24051.
4
Clinical characteristics and predictive value of lower CD4T cell level in patients with moderate and severe COVID-19: a multicenter retrospective study.中重度 COVID-19 患者中较低的 CD4T 细胞水平的临床特征和预测价值：一项多中心回顾性研究。
BMC Infect Dis. 2021 Jan 12;21(1):57. doi: 10.1186/s12879-020-05741-w.
5
CD4+CD25+CD127-Foxp3+ and CD8+CD28- Tregs in Renal Transplant Recipients: Phenotypic Patterns, Association With Immunosuppressive Drugs, and Interaction With Effector CD8+ T Cells and CD19+IL-10+ Bregs.肾移植受者中的CD4+CD25+CD127-Foxp3+和CD8+CD28-T调节性T细胞：表型模式、与免疫抑制药物的关联以及与效应性CD8+T细胞和CD19+IL-10+B调节性细胞的相互作用
Front Immunol. 2021 Jul 15;12:716559. doi: 10.3389/fimmu.2021.716559. eCollection 2021.
6
Dynamic changes in lymphocyte subsets and parallel cytokine levels in patients with severe and critical COVID-19.重症和危重症新型冠状病毒肺炎患者淋巴细胞亚群及相关细胞因子水平的动态变化
BMC Infect Dis. 2021 Jan 18;21(1):79. doi: 10.1186/s12879-021-05792-7.
7
CD4+CD25+ Regulatory T Cells Decreased CD8+IL-4+Cells in a Mouse Model of Allergic Asthma.在过敏性哮喘小鼠模型中，CD4+CD25+调节性T细胞减少了CD8+IL-4+细胞。
Iran J Allergy Asthma Immunol. 2019 Aug 17;18(4):369-378. doi: 10.18502/ijaai.v18i4.1415.
8
The predictive role of lymphocyte subsets and laboratory measurements in COVID-19 disease: a retrospective study.淋巴细胞亚群和实验室检测在 COVID-19 疾病中的预测作用：一项回顾性研究。
Ther Adv Respir Dis. 2021 Jan-Dec;15:17534666211049739. doi: 10.1177/17534666211049739.
9
Epidemiological and Clinical Characteristics of 217 Cases of COVID-19 in Jiangsu Province, China.中国江苏省 217 例 COVID-19 的流行病学和临床特征。
Med Sci Monit. 2021 Apr 12;27:e930853. doi: 10.12659/MSM.930853.
10
COVID-19 patients display changes in lymphocyte subsets with a higher frequency of dysfunctional CD8lo T cells associated with disease severity.COVID-19 患者的淋巴细胞亚群发生变化，功能失调的 CD8lo T 细胞频率更高，与疾病严重程度相关。
Front Immunol. 2023 Sep 21;14:1223730. doi: 10.3389/fimmu.2023.1223730. eCollection 2023.

引用本文的文献

1
Immune Checkpoints Receptors Expression of Macrophage/Monocytes in Response to Acute Viral Respiratory Infection.巨噬细胞/单核细胞在急性病毒性呼吸道感染反应中的免疫检查点受体表达
J Clin Med Res. 2024 May;16(5):232-242. doi: 10.14740/jocmr5098. Epub 2024 May 29.
2
Comparison of Diabetic Ketoacidosis Characteristics During- and Before the COVID-19 Pandemic.2019年冠状病毒病大流行期间与大流行之前糖尿病酮症酸中毒特征的比较
Int J Endocrinol Metab. 2023 Jun 18;21(3):e134882. doi: 10.5812/ijem-134882. eCollection 2023 Jul.
3
Phenotypical changes of hematopoietic stem and progenitor cells in COVID-19 patients: Correlation with disease status.

本文引用的文献

1
T cell response in patients with COVID-19.新型冠状病毒肺炎患者的T细胞反应
Blood Sci. 2020 Jul 25;2(3):76-78. doi: 10.1097/BS9.0000000000000050. eCollection 2020 Jul.
2
Association of follicular helper T and follicular regulatory T cells with severity and hyperglycemia in hospitalized COVID-19 patients.住院COVID-19患者中滤泡辅助性T细胞和滤泡调节性T细胞与疾病严重程度及高血糖的关联
Virulence. 2022 Dec;13(1):569-577. doi: 10.1080/21505594.2022.2047506.
3
Regulatory T cells: A potential weapon to combat COVID-19?调节性T细胞：对抗新冠病毒的潜在武器？
COVID-19患者造血干细胞和祖细胞的表型变化：与疾病状态的相关性。
Cent Eur J Immunol. 2023;48(2):97-110. doi: 10.5114/ceji.2023.129981. Epub 2023 Jul 17.
4
T Cell Response to SARS-CoV-2 Coinfection and Comorbidities.T细胞对SARS-CoV-2合并感染及合并症的反应。
Pathogens. 2023 Feb 15;12(2):321. doi: 10.3390/pathogens12020321.
5
Incidence of diabetic ketoacidosis during COVID-19 pandemic: a meta-analysis of 124,597 children with diabetes.COVID-19 大流行期间糖尿病酮症酸中毒的发生率：对 124597 例糖尿病儿童的荟萃分析。
Pediatr Res. 2023 Apr;93(5):1149-1160. doi: 10.1038/s41390-022-02241-2. Epub 2022 Aug 11.
MedComm (2020). 2020 Aug 6;1(2):157-164. doi: 10.1002/mco2.12. eCollection 2020 Sep.
4
COVID-19 and comorbidities: Deleterious impact on infected patients.COVID-19 与合并症：对感染患者的有害影响。
J Infect Public Health. 2020 Dec;13(12):1833-1839. doi: 10.1016/j.jiph.2020.07.014. Epub 2020 Aug 4.
5
T cell responses in patients with COVID-19.新冠病毒肺炎患者的T细胞反应
Nat Rev Immunol. 2020 Sep;20(9):529-536. doi: 10.1038/s41577-020-0402-6. Epub 2020 Jul 29.
6
Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications.深度免疫剖析 COVID-19 患者，揭示具有治疗意义的不同免疫类型。
Science. 2020 Sep 4;369(6508). doi: 10.1126/science.abc8511. Epub 2020 Jul 15.
7
Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: a retrospective and observational study.乳酸脱氢酶，重症新型冠状病毒肺炎患者的独立危险因素：一项回顾性观察研究
Aging (Albany NY). 2020 Jun 24;12(12):11245-11258. doi: 10.18632/aging.103372.
8
Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia.COVID-19 肺炎患者中标记的 T 细胞激活、衰老、衰竭和向 TH17 的倾斜。
Nat Commun. 2020 Jul 6;11(1):3434. doi: 10.1038/s41467-020-17292-4.
9
Serum ferritin as an independent risk factor for severity in COVID-19 patients.血清铁蛋白作为新冠病毒肺炎患者病情严重程度的独立危险因素。
J Infect. 2020 Oct;81(4):647-679. doi: 10.1016/j.jinf.2020.06.053. Epub 2020 Jun 24.
10
Immunology of COVID-19: Current State of the Science.COVID-19 的免疫学：科学现状。
Immunity. 2020 Jun 16;52(6):910-941. doi: 10.1016/j.immuni.2020.05.002. Epub 2020 May 6.